Study #2019-0172
TELLOMAK: T-Cell Lymphoma Anti-KIR3DL2 Therapy an Open Label, Multi- Cohort, Multi-Center Phase II Study Evaluating the Efficacy and Safety of Iph4102 Alone or In Combination with Chemotherapy in Patients with Advanced T-Cell Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
IPH4102
Description
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
Study phase:
Phase II
Physician name:
Auris Huen
Department:
Dermatology
For general questions about clinical trials:
1-844-955-5036
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.